The development of MeTA requires the disclosure, validation and analysis of a core set of data which includes:
- medicines registration and quality assurance
- the availability of medicines
- the price of medicines
- the policies and practices concerning the promotion of medicines
Without this information, progress in identifying and tackling the policies and practices which limit access to essential medicines cannot be made.
However, the disclosure of information in the pharmaceutical sector is often minimal. The private sector is sometimes reluctant to share information that might put it at a competitive disadvantage. Disclosure that might expose unethical government practices or bureaucratic and system inefficiencies is often resisted – and might even jeopardise the process as a whole.
The tools in this section therefore provide strategies and methodologies which facilitate the disclosure of this information in a way that all parties find acceptable and helpful – and that maximises the data ‘on the table’ while minimising exposure. This might include incremental disclosure, aggregated information, or limiting those with whom the information is initially shared, with the ultimate aim of making this information available to broader constituencies.
- Pharmaceutical Sector Scan
- Data Disclosure Survey
- Household & Facility Surveys on Access to and Rational Use of Medicines in Countries
- Measuring Medicine Prices, Availability, Affordability and Price Components
- Medicines Promotion: Assessing the Nature, Extent and Impact of Regulation
- Assessing Government Procurement and Transparency
- Drug and Therapeutics Committees (DTC) - A Practical Guide
- Measuring Transparency in the Public Pharmaceutical Sector
- Medicine Price Components
- Medicine Price and Availability Monitoring
- Pharmaceutical Country Profile
- Procurement and Supply Management (PSM) Toolbox